Traders should monitor the outcome of the FDA Type C meeting in Q1 2026, which could trigger a significant move on NDA submission prospects. The reduced burn rate improves survival odds, but the $28M offering implies future dilution across tranches.
Price Chart
Executive Summary
Clene Inc. reported its 2025 financial results, highlighted by a 33% reduction in net loss to $26.2 million and an oversubscribed $28 million registered direct offering that extends cash runway into 2027. The company is preparing for a pivotal FDA Type C meeting on CNM-Au8 for ALS, with an NDA submission planned by end of Q2 2026 if the meeting is favorable.
Key Financial Metrics
Key Facts
- Net loss decreased to $26.2 million in 2025 from $39.4 million in 2024, with EPS improving from -$5.67 to -$2.65.
- Cash and cash equivalents declined to $5.2 million as of December 31, 2025, from $12.2 million a year prior.
- Oversubscribed $28 million registered direct offering completed in January 2026, with initial tranche of $6 million providing runway to Q3 2026.
- Type C FDA meeting scheduled by end of Q1 2026 to discuss biomarker and survival data for CNM-Au8 in ALS; NDA filing planned by end of June 2026 if successful.
- Biomarker data showed statistically significant reductions in NfL and GFAP, correlating with prolonged survival in ALS patients.
- R&D expenses decreased to $14.0 million from $20.1 million due to completion of key trials, partially offset by increased NIH-EAP enrollment.
Financial Impact
Net loss reduced by $13.2 million YoY; $28 million in new financing secured with milestone-linked tranches extending into 2027.
Risk Factors
- FDA may not support accelerated approval based on biomarker data alone.
- Additional financing tranches are contingent on regulatory milestones, creating execution risk.
- High cash burn and existing debt load ($12.2M in notes and convertible notes) increase financial pressure.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3254582 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | 8-K | $3.73 | awaiting T+20 | — | $3.84 (+2.95%) |
Oct 19, 2026 7d ago | 8-K | $3.29 | awaiting T+20 | — | $3.84 (+16.72%) |
Oct 19, 2026 7d ago | Press Release | $3.29 | awaiting T+20 | — | $3.84 (+16.72%) |
Oct 13, 2026 13d ago | SC 13G/A | $3.39 | awaiting T+20 | — | $3.84 (+13.27%) |
Sep 16, 2026 5w ago | 8-K | $4.15 $3.31 | ▲ +20.36% | ▲ +21.57% | $3.84 (+7.47%) |
Sep 16, 2026 5w ago | 424B5 | $3.86 $3.31 | ▲ +14.25% | ▲ +16.31% | $3.84 (+0.52%) |
Aug 14, 2026 10w ago | 8-K | $4.14 $3.28 | ▼ −20.77% | ▼ −18.78% | $3.84 (−7.25%) |
Aug 14, 2026 10w ago | Press Release | $4.14 $3.28 | ▼ −20.77% | ▼ −18.78% | $3.84 (−7.25%) |
Aug 10, 2026 11w ago | 8-K | $5.16 $3.62 | ▼ −29.84% | ▼ −28.93% | $3.84 (−25.58%) |
May 14, 2026 23w ago | 8-K | $7.05 $5.84 | ▼ −17.16% | ▼ −16.30% | $3.84 (−45.53%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers